BridgeBio to Unveil Phase 3 Trial Results for Rare Genetic Condition Treatment

Event summary

  • BridgeBio will present primary results from the Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1) at the 2026 European Congress of Endocrinology (ECE).
  • The oral presentation on encaleret's primary results is scheduled for May 12, 2026, at 11:50 am CEST.
  • Additional data from the CALIBRATE trial and other studies will be shared through one oral presentation, one poster, and one ePoster at the ECE.
  • The trial aims to address a rare genetic condition with limited treatment options.

The big picture

BridgeBio's presentation of Phase 3 trial results for encaleret underscores the company's focus on developing treatments for rare genetic conditions. The success of encaleret could set a precedent for other therapies targeting underserved patient populations, highlighting the strategic importance of genetic medicine in the biopharmaceutical industry. The results will be closely watched by investors and analysts for their potential to drive future growth and partnerships.

What we're watching

Clinical Efficacy
How the primary results from the CALIBRATE trial will impact the regulatory pathway for encaleret.
Market Potential
Whether BridgeBio can leverage these results to expand its portfolio in rare genetic conditions.
Competitive Landscape
The pace at which other biopharmaceutical companies are developing treatments for ADH1 and similar conditions.